Ovarian cancer represents a malignancy suitable for cell and gene therapy approaches owing to its containment within the peritoneal cavity, even at advanced tumor stages. As regulation of transgene expression would be preferable for conducting clinical trials for reasons of safety, we investigated whether intraperitoneal (i.p.) administration of retroviral vector-transduced fibroblasts encoding murine interferon-a (IFN-a) could have therapeutic activity, and compared its effect with the antitumor effects of fibroblasts producing IFNa under a rapamycin analogue (AP21967)-inducible promoter. Human and murine fibroblasts were recruited into the solid component of transplantable ovarian cancer-grown i.p. in severe combined immunodeficiency mice. Multiple administrations of fibroblasts producing IFN-a in a constitutive manner showed therapeutic efficacy, leading to significant prolongation of survival in the majority of animals, associated with inhibition of tumor angiogenesis. Compared to cells transduced by the constitutive vector, fibroblasts transduced by the inducible vector released twofold higher IFN-a levels in vitro, following induction by AP21967, and production of the cytokine was under pharmacologic control both in vitro and in vivo. However, these cells elicited only modest therapeutic effects in vivo. Overall, these findings indicate that intracavitary IFN-a gene therapy using engineered fibroblasts requires sustained production of IFN-a to achieve durable antitumor effects. Gene Therapy (2006) 13, 953-965.
Introduction
Ovarian carcinoma is a leading cause of death owing to gynecologic malignancies both in Europe and North America. 1 Owing to the lack of effective screening strategies and the possible absence of symptoms during early stage of disease, about 70% of patients present with advanced disease. Furthermore, although initially amenable to be treated by surgery and chemotherapy, a maintenance therapy is currently lacking, exposing many patients to the risk of relapses, which have often a dismal prognosis. Because of this, the long-term survival for patients with advanced disease is still about 30%, prompting the development of novel therapies, especially to prevent recurrences. Gene therapy has been considered for ovarian carcinoma, mainly because nearly 90% of women have disease contained within the peritoneal cavity, which allows for relatively easy delivery of viral vectors through intraperitoneal (i.p.) injections (reviewed in Kirby et al. 2 and Zeimet and ). However, strategies involving injection of viral vectors have had so far limited clinical application, because of the lack of sufficient specificity and efficient gene transfer, and the absence of control of the expression of the therapeutic gene.
Because of these current limitations, we have considered an alternative strategy, that is to modulate angiogenesis in the tumor microenvironment by cell therapy with ex vivo-transduced cells, and we have recently shown that human fibroblasts (HF) are recruited by the stroma of ovarian cancer and localize close to tumor-associated blood vessels, without substantial homing to normal tissues. 4 The use of autologous fibroblasts for regional ovarian cancer gene therapy is considered feasible, as fibroblasts from ovarian cancer patients can be easily obtained from tumor biopsies, 5 or from the skin.
We and others have recently found that IFN-a is endowed with marked antiangiogenic activity in breast cancer and glioma tumor models, [6] [7] [8] and considered it a suitable candidate gene for this therapeutic approach. Moreover, several studies have previously addressed the therapeutic efficacy of cell therapy approaches with cytokines, including IL-2, IL-4, IL-12 and IFN-a in different experimental tumor models. 5, [9] [10] [11] [12] [13] [14] Although in preclinical models toxicity owing to cytokine overexpression has not been a limiting issue, it is fully understandable that regulatable vectors would be greatly preferable to conduct clinical trials with cytokine genes in humans. However, it is unclear whether the preliminary promising results obtained with constitutively active vectors could also be attained with inducible vectors. To investigate this, we compared the therapeutic efficacy of a cell therapy approach with fibroblasts engineered with either a constitutive or an inducible retroviral vector encoding murine IFN-a, and report on the differences observed in terms of transgene expression profiles and therapeutic outcome. The data presented may be of interest in the design of future cell therapy approaches for ovarian cancer.
Results

Evaluation of transgenic fibroblast recruitment into IGROV-1 tumors
We have recently reported that both LacZ-tagged HF and endothelial cells home to IGROV-1 tumors, following i.p. injection into severe combined immunodeficiency (SCID) mice. 4 Interestingly, these cells appear to localize into distinct compartments of the tumor microenvironment, as endothelial cells home to tumor-associated blood vessels, whereas fibroblasts form clusters within the stroma. 4 To measure more precisely the degree of incorporation of different types of fibroblasts into these tumors, we transduced both HF and murine fibroblastic cells (NIH3T3) with an enhanced green fluorescent protein (EGFP)-coding retroviral vector, and followed their homing into IGROV-1 tumors by both stereoscopic and confocal microscopy analysis and flow cytometry. Confocal microscopy analysis of EGFP expression in IGROV-1 tumors. Tumor sections were fixed and subjected to indirect immunofluorescence. Fixed sections were stained with propidium iodide and rabbit anti-GFP antibody (Ab), followed by Alexa 488-conjugated goat anti-rabbit secondary Abs before being analyzed by confocal microscopy. In confocal laser scanning images of tumor sections, the green signals correspond to EGFP, whereas red signals correspond to the nuclear staining determined by propidium iodide. Yellow signals generated in the overlay show the colocalization of EGFP and propidium iodide, highlighting the presence of clusters of EGFP + fibroblasts in the tumors. Some areas spanning EGFP + cells were quantified using the Zeiss Profile software tool to compare the intensities of the EGFP and the propidium iodide signals along a line traced across several cells (a and b): results are presented as a graph showing the relative intensities of the EGFP (green) and the PI (red) channels (y axis) against the distance (in micrometer) from the origin of the line. The bar corresponds to 50 mm. (c) Quantitative analysis of EGFP + fibroblasts performed on single-cell suspensions obtained through mechanical dissociation of the tumors. Cells were analyzed for EGFP expression on an EPICSElite cytofluorimeter. The percentage of EGFP-expressing cells is indicated. The panels show the representative analysis of one tumor injected with EGFP-tagged human fibroblasts (HF-EGFP+), one tumor injected with EGFP+ murine fibroblasts (NIH-EGFP+) and two control tumors (mock).
Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al same numbers of HF at later time points, following tumor cell injection (days 16-20-24) , was associated with a marked reduction (0.270.1%) of these cells into tumors, indicating that the efficiency of this phenomenon partially depends on the tumor stage.
Evidence of interferon-a 1 production in vivo
Human fibroblasts were transduced with the retroviral vector LmuIFN-a 1 SN ( Figure 2 ) and selected in G418 for 2 weeks as detailed in Materials and methods. Interferona production by HF-IFN was evaluated by ELISA in the supernatants of HF-IFN obtained from three different primary cultures, and it was 2891.871516.0 pg/ml/10 6 cells in 24 h. Repeated sampling over a 4-week interval showed that IFN-a levels were substantially stable in these cultures. To determine the local and systemic levels of IFN-a 1 after i.p. injection of HF-IFN, animals (n ¼ 4/ group) received IGROV-1 cells, followed, 4 days later, by a single i.p. dose of 2 Â 10 6 HF-IFN cells. One week later, the mice were killed, and the levels of murine IFN-a 1 in serum and peritoneal washing fluid were determined by ELISA. Serum levels were below the detection limits of our assay (12.5 pg/ml) in all samples, whereas i.p. levels were 1796.5784.5 pg/ml. Intraperitoneal levels of IFN-a 1 in control mice, which received IGROV-1 cells followed by HF transduced by the control LXSN vector, were 42.375.0 pg/ml; as many normal cell types can produce IFN-a following appropriate stimulation, 15 it is possible that these low levels are due to endogenous IFN secretion by murine cells within the peritoneal cavity in response to tumor growth. On the other hand, HF-IFN cells injected into SCID mice without prior tumor cell administration produced 1248.1750.4 pg/ml IFN-a (Figure 3a) .
In the same experiment, indirect evidence of IFN-a production in vivo was obtained by investigating the expression of the IFN-regulated Ly-6C marker in cells contained in the peritoneal lavage fluids and splenocytes. Ly-6C is a murine surface antigen expressed by both monocytes and lymphoid cells, and is induced by class I IFNs. 16 One week after vector injection, Ly-6C was strongly expressed in 55.575.6% of cells in peritoneal lavage fluids from SCID mice injected with the HF-IFN, whereas it was expressed by 7.471.2% of the cells from control animals ( Figure 3b) ; Ly-6C expression in splenocytes of IFN-treated mice was also increased compared to controls (27.575.6 versus 6.172.2%). Appreciable Ly-6C upregulation was still demonstrated 28 days after injection of IFN-producing HF, thus indicating persistent biological activity.
Antitumor activity of intraperitoneal injections of HF-IFN into ovarian cancer-bearing mice
To assess the therapeutic efficacy of the administration of IFN-producing HF, we utilized ovarian cancer-bearing SCID mice. In a first series of in vivo experiments, relatively high HF-IFN numbers (2 Â 10 6 cells/injection) were inoculated on days 4, 8 and 12 i.p. into SCID mice, which had received 1 Â 10 6 IGROV-1 ovarian cancer cells by the same route on day 0. All control animals died by day 40, with no significant differences between salineand HF-LXSN-injected animals ( Figure 3c ). In contrast, animals injected with three doses of murine IFN-a 1 -producing fibroblasts had a 100% survival until day 60, and then started to succumb (Figure 3c ). Median survival was 83 days and significantly prolonged compared to controls (Po0.005).
To further explore the characteristics of the therapeutic effect of HF-IFN, different approaches were performed using the IGROV-1 model. In a first dose-response experiment, groups of five mice injected with IGROV-1 cells on day 0 were treated on days 4, 8 and 12 with 2 Â 10 6 , 1 Â 10 6 , 5 Â 10 5 and 2 Â 10 5 HF-IFN, and were followed up for survival. As shown by the Kaplan-Meier survival curves (Figure 3c ), a certain dose-response correlation was seen: in fact, animals that had received a lower cumulative dose of 0.6 Â 10 6 or 1.5 Â 10 6 IFNengineered HF had only a slight, albeit significant, increase in their survival, compared to controls (Figure  3c ), whereas a more pronounced therapeutic effect was (IFN-a 1 ) under the constitutively active Mo-MLV promoter/enhancer and also bearing an internal G418-resistance cassette has been described previously. 30 The plasmid L 2 N 2 -R H S3H/ZF3 encodes the activation and the DNA-binding domains of the rapamycin-sensitive recombinant transcription factor, as reported previously. 17 The vector carries a neomicin-resistance cassette between the DNA-binding component of the transcription factor and the 3 0 -end LTR. The LH-Z 12 I-muIFN-a 1 vector carries 12 ZFHD1 binding sites and a minimal interleukin (IL)-2 gene promoter driving the expression of murine IFN-a 1 ; a hygromycin-resistance cassette is inserted between the extended vector packaging signal (c) and the ZFHD1 binding sites.
Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al observed in mice that received higher cumulative doses (3 Â 10 6 and 6 Â 10 6 HF-IFN) (Figure 3c ). In a second approach to establish whether HF-IFN would be effective against larger tumors, we varied the time of fibroblast injection after tumor cell inoculation. Groups of five mice were thus injected with IGROV-1 cells on day 0; starting on day 4, 8 or 16, the mice received every fourth day 1 Â 10 6 HF-IFN, for a total amount of 3 Â 10 6 fibroblasts in all mice. As shown in Figure 3d , control animals died rapidly with a median survival of 35 days. All treated groups showed increased survival, compared to control animals with a clear correlation with the timing of HF-IFN injection. Animals injected on days 4-8-12 after tumor cell injection had an increase in median survival to 76 days (Po0.005). In contrast, animals with larger tumors treated on days 16-20-24 had a less marked but still significant (Po0.05) increase in median survival (54 versus 35 days). The group of mice treated on days 8-12-16 behaved similarly to those receiving HF-IFN on days 16-20-24 (Figure 3d ).
These studies demonstrate that multiple doses of the IFN-a 1 -producing human primary fibroblasts are remarkably effective in treating ovarian carcinoma as an early treatment strategy.
Construction and retroviral delivery of rapamycinregulated transcription factors
For retroviral delivery of rapamycin-responsive transcription factors, we assembled a series of LXSN-derived constructs, the basic structure of which is shown in Figure 2 . Transcription factors are expressed from an LTR-driven transcription unit containing an internal ribosome entry site that permits expression of both transcription factor fusions from a single bicistronic message. The vector also contains an internal neomycin Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al phosphotransferase expression cassette that allows stably transduced cells to be isolated by using G418 selection. Owing to the relatively low titer of the inducible vectors, which precluded the possibility of transducing primary HF, we used NIH3T3 cells, which are transduced very efficiently by retroviral vectors and can be easily selected in G418-containing medium. The NIH3T3-L 2 N 2 -R H S3H/ZF3 cells were next transduced with the LH-Z 12 I-muIFN-a 1 vector and selected in hygromicin-containing medium to obtain a stably double-transduced NIH3T3 derivative, which was termed NIH3T3-IFN ind , and were assayed for rapamycin-dependent IFN-a production. We also transduced NIH3T3 with the retroviral vector LmuIFN-a 1 SN and, following G418 selection, obtained a cell population constitutively expressing IFN-a, which was termed NIH3T3-IFN const and used in subsequent experiments.
Although the retroviral vector system is fully responsive to rapamycin, in our experiments the rapamycin analogue AP21967 was used, because it was considered to be more appropriate in a possible clinical setting. In fact, AP21967 is a chemically modified non-immunosuppressive compound, which can induce heterodimerization of FKBP and FRB T2098L -containing fusion proteins, which are encoded by the vector, and does not interfere with the activity of the endogenous FRAP kinase.
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NIH3T3-IFN
ind showed murine IFN-a expression after a 24 h incubation with AP21967 at concentrations of 10 ng/ml or greater (Figure 4a ): the 100 ng/ml concentration was found to yield highest levels of transgene induction and it was utilized thereafter. Next, we analyzed the kinetics of IFN-a production following AP21967 stimulation. Peak levels were reached 24 h later, and IFN-a concentrations progressively decreased over the following 96 h, returning to prestimulation levels by day 5. Re-stimulation with AP21967 on day 7 was capable of inducing IFN-a production with a similar kinetics ( Figure 4b ). Notably, peak levels of IFN-a were about twofold higher than average levels measured in the supernatants of NIH3T3-IFN const cells (Figure 4b ). Finally, we investigated the effects of multiple inductions with AP21967 on IFN-a production: as shown in Figure 4c , a 3-weekly induction schedule did not improve peak levels of IFN-a; however, it was capable of slowing the drop of IFN levels to the prestimulation levels, which is typically observed by day 6 in the supernatants from NIH3T3-IFN ind cells stimulated once a week with AP21967. These results indicate that the split inducible system supports robust, tightly regulated transcription of the transgene in murine fibroblasts.
Effects of AP21967 on tumor cell proliferation and production of angiogenic factors
In view of the reported cytostatic activity of rapamycin and related drugs targeting the mTOR pathway, 18 and being aware that AP21967 has reduced but still present inhibitory activity on mTOR (T Clackson and V Rivera, personal communication), we were interested in investigating the effects of AP21967 on the proliferation of ovarian cancer cells. IGROV-1 cells were cultured in the presence of increasing concentrations of AP21967 or rapamycin, and cell proliferation was measured 3 days later by an MTT assay. As shown in Figure 5a , AP21967 exerted a weak dose-dependent cytostatic effect on IGROV-1 cells, with reduction of cell proliferation by 33% at the highest concentration, compared to a 45% reduction in cell proliferation produced by rapamycin at the same dose. Cis-platinum (10 mg/ml) was used as a positive control and inhibited cell proliferation by 490% in the same assay. Comparable figures were obtained on NIH3T3 cells, with about 22% reduction by AP21967 in cell proliferation compared to controls at the highest dose (Figure 5a ). ind cells were plated as above; after 24 h, the cells were induced with AP21967 (100 ng/ml), and culture medium was replaced daily. Supernatants were collected at 24 h intervals and analyzed for IFNa content by ELISA. On day 7, induction was repeated as detailed above. The production of IFN-a by NIH3T3-IFN const cells was evaluated at the same time points. (c) Kinetics of IFN-a production following multiple induction with AP21967. The experiment was conducted as detailed in (b), except for the different schedule of incubation with AP21967: the arrows indicate at which time points AP21967 was added to the cultures (100 ng/ml). Supernatants were collected at 24 h intervals and analyzed for IFN-a content by ELISA.
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Finally, because rapamycin has been reported to downregulate vascular endothelial growth factor (VEGF) expression, 19 we measured human VEGF levels in the supernatants of IGROV-1 cells treated with AP21967: a dose-dependent reduction in VEGF levels was measured, albeit less intense compared to that induced by rapamycin (Figure 5b ). On the other hand, AP21967 did not reduce the levels of IL-8 produced by IGROV-1 cells (Figure 5b ), thus showing that the production of other angiogenic factors by cancer cells remained unchanged. In conclusion, AP21967 exerted weaker cytostatic effects and impaired only minimally VEGF production by IGROV-1 cells compared to the parental compound rapamycin, thus supporting its exploitation in vivo to evaluate the therapeutic efficacy of different modalities of IFN-a production.
Comparison of the therapeutic efficacy of inducible and constitutive interferon-a expression systems
We sought to assess the performance of the split inducible system in vivo and to compare levels of induced gene expression and therapeutic efficacy with those obtained from a constitutive LTR-driven vector. IGROV-1 ovarian cancer cells were injected i.p. into SCID mice, followed on day 4 by a single injection of 2 Â 10 -receiving mice were split into two groups: one group received AP21967 and the second group received solvent alone (n ¼ 8 mice/group). Two groups of mice were given NIH3T3-LXSN cells, which have been transduced by the control vector LXSN, either with or without AP21967. Survival curves of this experiment are shown in Figure 6b . We observed that NIH3T3-IFN const cells exerted an antitumor effect, with extension of median survival to 59 days, compared to controls, which succumbed by day 32 (Po0.002). However, NIH3T3-IFN ind cells were less effective in controlling tumor growth: median survival was slightly prolonged (42 days), yet not significantly compared to controls. In any case, AP21967 administration to control mice did not extend survival (Figure 6b) .
To control IFN-a production in this experiment, while maintaining the animals alive, we bled them 2 days after Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al each weekly administration of AP21967 and investigated the expression at the mRNA level of IRF-7, an interferoninducible gene, 20 in peripheral blood mononuclear cells (PBMC). We observed upregulation of IRF7 expression in the majority of the PBMC samples of SCID mice injected with NIH3T3-IFN ind and treated with AP21967 ( Figure  6c ), which confirmed that the IFN-a produced following AP21967 activation was sufficient to generate a sustained biologic response.
Evidence of angiogenesis inhibition by interferon-aproducing fibroblasts
Interferon-a is a cytokine endowed with pleiotropic effects in many tumor models. In previous work, we observed that its antitumor effect in several cancer tumor models was mainly because of angiogenesis inhibition. 7, 8 We therefore investigated the contribution of this phenomenon in the ovarian cancer model reported here. IFN-a-treated tumors were characterized by the presence of areas of necrosis, surrounded by infiltrating mononuclear cells, which were less represented in control tumors (Figure 7a ). Microvessel density (MVD) was 4.072.2 and 13.772.1 in IFN-treated and control tumors (n ¼ 3 mice/group), respectively (Po0.05), as evaluated by performing immunohistochemistry with an anti-CD31 monoclonal antibody (mAb) (Figure 7a ). Moreover, IFN-a-treated tumors contained several apoptotic endothelial cells, as shown by confocal microscopy analysis of tumor sections stained with an antibody (Ab) against activated caspase-3 (Figure 7b) . Overall, these findings show that angiogenesis inhibition is one of the mechanisms contributing to the antitumor effect in this experimental model.
Because in other systems antitumor effects of IFN-a have been attributed to immunologic mechanisms, 15 we also evaluated the possible contribution of NK cells. We did not find evidence of an increase in NK cells in peritoneal fluids from IFN-a-treated mice, as evaluated by staining with an anti-mouse pan-NK cells mAb, followed by flow cytometric analysis (Figure 7c) . Splenocytes of the same animals contained a larger population of DX5 + cells (Figure 7c ), which did not appreciably differ between IFN-a-treated mice and controls. Moreover, treatment of mice with anti-asialo GM1, an NK-depleting Ab, resulted in a nonsignificant reduction in the therapeutic effect (Figure 7d ), indicating only a limited contribution of NK cells to the antitumor effect.
Discussion
Fibroblasts have been often used for cell therapy approaches of both heritable diseases and cancer, owing The arrows indicate murine blood vessels, which are less abundant in IFN-a-treated tumor samples. Scale bar ¼ 100 mm. (b) Apoptosis in IGROV-1 tumors by confocal microscopy analysis. Tumor sections were fixed and subjected to indirect immunofluorescence. Fixed sections were stained with TO-PRO-3, rat anti-CD31 and rabbit anti-cleaved caspase 3, followed by Alexa 594-conjugated goat anti-rat or Alexa 488-conjugated goat anti-rabbit secondary Abs before being analyzed by confocal microscopy. In confocal laser scanning images of tumor sections, the green signals correspond to activated caspase 3, whereas red signals correspond to CD31. The nuclear staining was determined by TO-PRO-3 staining. Yellow signals generated in the overlay show the colocalization of activated caspase 3 and CD31, highlighting the presence of apoptotic endothelial cells in the tumors. The bar corresponds to 50 mm. 
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to the feasibility of obtaining them from skin biopsy or other tissues, and the efficient gene transfer into these cells by using both viral and non-viral gene delivery methods. The limited capability of replication and lack of self-renewal properties of these cells, compared to various types of stem cells, could represent an advantage from the point of view of safety, because adverse effects related to insertional mutagenesis of the transgene are unlikely to occur. Some clinical trials with genetically modified fibroblasts encoding coagulation factor VIII have recently shown hints of efficacy in hemophilia A. 21 In cancer patients, peritumoral injection of IL-12-producing autologous fibroblasts has been used in a phase I clinical trial, and this approach has been shown to be safe, and some transient clinical responses have been observed. 22 Notably, all ongoing clinical trials with fibroblasts have so far been based on the delivery of genetically modified cells with constitutive transgene production.
In preclinical models, the use of fibroblasts to deliver IFN-a into tumors has been pioneered by Tü ting et al. 9 in a TS/A mouse mammary adenocarcinoma model. In that study, murine embryonic fibroblast lines were stably transduced with retroviral vectors and coinjected subcutaneously with tumor cells in immunocompetent mice: this resulted in suppression of the establishment of TS/A adenocarcinoma and the induction of antitumor immunity.
In this study, we sought to investigate the therapeutic efficacy of this approach in an i.p. model of ovarian cancer by exploiting human primary fibroblasts as the vehicle of IFN-a. Because regulatable vectors would be greatly preferable to constitutive vectors to conduct clinical trials in humans, in order to temporally restrict transgene expression, we compared therapeutic efficacy in the same preclinical model. Our key findings are as follows.
First, we showed that recruitment of fibroblasts into these tumors occurs, albeit with low efficiency, as exogenously administered fibroblasts accounted for 0.3-1.4% of the total cells and they mainly localized at the surface of tumor nodules. Nevertheless, this small cell population exerted a dramatic effect on survival, especially if it was delivered at early time points following tumor cell injection. This is likely explained by the very strong antitumor activity of IFN-a, which has previously been observed in glioma and breast cancer models. 8, 23 Notably, injection of fibroblasts at later time points was associated with less efficient recruitment into the tumor, a finding that could at least partially explain the reduced therapeutic efficacy on established tumors. Overall, these findings indicate that production of IFN-a within the tumor microenvironment could be useful to delay ovarian cancer progression. The clinical situation that more likely could profit from this therapy would be minimal residual disease following surgery and chemotherapy, where the number of residual tumor cells could be low enough to allow transfer of adequate proportions of IFN-producing fibroblasts. On the other hand, it remains to be verified whether adult fibroblasts, which would be obtainable from patients, behave similarly to newborn fibroblasts, which were used in this study, in terms of proliferative capacity and recruitment efficiency into tumors.
Second, we showed that it is feasible to generate an inducible retroviral vector for IFN-a based on the previously described rapamycin system. This system exploits fully human components and it is thus presumed to be useful for clinical applications, because the vector components are likely non-immunogenic 24 and rapamycin and its derivatives are approved for clinical use. 25 Moreover, in the absence of rapamycin, no or minimal baseline expression in vitro or in vivo has been reported. 24, 26 Induction of IFN-a production following administration of the rapamycin analogue AP21967 was rapid in vitro, and lasted for about 4 days. Repeated inductions were possible; however, re-induction at 48 h interval was only partially useful to maintain sustained IFN levels. The mechanism underlying this observation is currently unknown.
In our experiments, aimed primarily at comparing the therapeutic efficacy of constitutive versus inducible IFNa production, we used AP21967, rather than rapamycin, in order to minimize the possible direct antitumor effects of the dimerizer. Indeed, published data suggested that rapamycin could have greater antiproliferative 18, 27 and antiangiogenic effects than AP21967. 19, 28 This was also confirmed by the results of our in vitro assays, which indicated that rapamycin reduced both cell proliferation and VEGF production by IGROV-1 cells in vitro, at much lower concentrations than AP21967. The modest effects of AP21967 on VEGF production, along with compensatory mechanisms, which may include production of other angiogenic factors (such as IL-8) by tumor cells, could explain the minimal effect of AP21967 administration on survival of SCID mice bearing IGROV-1 cells (Figure 6b) . In future studies, it will certainly be interesting to evaluate whether the combination of rapamycin and rapamycin-controlled IFN-a-producing fibroblasts with appropriate schedules of administration could have therapeutic synergism.
In vivo, we could provide evidence of responsiveness to AP21967, with direct measurement of IFN levels in the peritoneal washings of the treated animals, which were similar to those measured in samples obtained from mice injected with NIH3T3-IFN const cells. Disappointingly, however, this did not translate into a comparable therapeutic efficacy. This could partly depend on the highly divergent kinetics of IFN-a production by the two types of engineered cells: in fact, NIH3T3-IFN ind cells produced IFN-a in a transient fashion compared to NIH3T3-IFN const cells. This may indicate that sustained IFN-a production or the achievement of certain cumulative levels is needed to efficiently restrict ovarian cancer growth.
Interferon-a has been noted to elicit antitumor responses in immunocompetent mice and to contribute to the expansion of tumor-specific CD8 + T cells and activated NK cells, which could exert cytotoxic effects against tumor cells (reviewed by Belardelli et al.
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). Although T cells are obviously absent in SCID mice, activated NK cells could have contributed to the antitumor effects observed following cell therapy with IFN-producing HF. However, depletion of NK cells by treatment with anti-asialo GM1 Ab reduced but did not abolish the therapeutic effect of HF-IFN (Figure 7d ), thus suggesting that other mechanisms, including angiogenesis inhibition, which has been associated with IFN-a antitumor activity, 7, 8, 29 could be at work in this experimental system. In this regard, the observation that continuous IFN-a production achieved better tumor Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al control than intermittent production fits the hypothesis that IFN-a mainly operates through cytostatic rather than cytotoxic mechanisms. Moreover, the evidence of increased areas of necrosis, reduced blood vessel density and increased endothelial cell apoptosis within IFN-atreated tumors compared with controls (Figure 7a and b) strengthens this hypothesis as such. In conclusion, this study highlights the complex issues behind cell therapy approaches of cancer with engineered fibroblasts; this information may be useful in the design of future experimental strategies with IFN-a or other angiogenesis inhibitors in ovarian cancer models.
Materials and methods
Retroviral vectors
The retroviral vector LmuIFN-a 1 SN (Figure 2 ) expressing murine IFN-a1 under the constitutively active Mo-MLV promoter/enhancer and also bearing an internal G418 resistance cassette has been described previously. 30 The plasmids L 2 N 2 -R H S3H/ZF3 and LH-Z 12 I-PL, encoding the components of the inducible retroviral vector system, were obtained from ARIAD Inc. (Cambridge, MA, USA). L 2 N 2 -R H S3H/ZF3 encodes the activation and the DNAbinding domains of the rapamycin-sensitive recombinant transcription factor, as reported previously. 17 Briefly, the chimeric activation domain consists of the minimal FRB domain of human FRAP containing a threonine-toleucine mutation at amino acid 2098, termed T2098L, fused to amino acids 281-551 of the p65 subunit of human NF-kB fused to amino acids 406-530 of the human heatshock factor 1 (HSF1) transcription factor ( Figure 2 ). The chimeric DNA-binding domain contains three copies of FKBP12 (F3) fused to the ZFHD1 DNAbinding domain (Z). The vector carries a neomicinresistance cassette between the DNA-binding component of the transcription factor and the 3 0 -end LTR (Figure 2 ). The LH-Z 12 I-PL vector carries 12 ZFHD1 binding sites and a minimal IL-2 gene promoter; a hygromicinresistance cassette is inserted between the extended vector packaging signal (c) and the ZFHD1 binding sites (Figure 2) . Murine IFN-a 1 cDNA was subcloned from pcDNA3.1muIFN-a 1 into the EcoRI site of LH-Z 12 I-PL by standard cloning procedures; the resulting vector was named LH-Z 12 I-muIFN-a 1 (Figure 2) . The construct LESN, expressing EGFP under the Mo-MLV LTR, 31 was used in gene tracking experiments. The parental LXSN vector, lacking the IFN-a cDNA, was used as a control vector in some in vivo experiments.
The LmuIFN-a 1 SN retroviral vector ( Figure 2 ) was produced by a transfected GP+env Am12 packaging cell line, as reported previously. 30 All the other retroviral vectors used in this study were generated by exploiting the transient three-plasmid vector-packaging system based on 293T cells, as described previously. 32 The genomic RNA was packaged in retroviral particles produced by transfection of gag-polgpt, a plasmid carrying the genes coding for Mo-MLV Gag and Pol, and pseudotyped with the protein G of vesicular stomatitis virus (VSV-G). 7 
Cell lines
The NIH3T3 murine fibroblastic and 293T human kidney cell lines were obtained from ATCC (Manassas, VA, USA), and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS; Invitrogen, Milan, Italy). NIH3T3 and 293T cells were used for titration experiments and as a packaging cell line, respectively. IGROV-1 ovarian cancer cells were grown in RPMI 1640 medium (Euroclone, Milan, Italy) supplemented with 10% FCS and 1% L-glutamine (complete RPMI). Primary HF were obtained by mechanical disruption of the connective tissue of the umbilical cord, as described previously, 4 and cultured in complete DMEM.
Transduction of fibroblasts with retroviral vectors
Transduction of HF or NIH3T3 cells was performed by using cell-free supernatant. To this end, 1 ml of supernatant containing LESN, LXSN, LmuIFN-a 1 SN or L 2 N 2 -R H S3H/ZF3 vectors was incubated with 3 Â 10 4 target cells in six-well plates for 6 h at 371C; after this, the vector-containing supernatant was replaced with fresh medium. Seventy-two hours after transduction, cells were split and underwent selection in medium containing G418 (500 mg/ml; Invitrogen). By the end of the selection procedure (about 2 weeks later), fibroblasts were expanded to obtain cell numbers required for in vitro and in vivo experiments. To obtain NIH3T3-IFN cells were injected i.p. into SCID mice 4 days after the injection of tumor cells. To induce IFN-a production by NIH3T3 cells engineered with the inducible vectors, the rapamycin analogue AP21967 was formulated in 50% N,N-dimethylacetamide (DMA) and 50% PEG-400-Tween-80 (9:1) (both from Sigma-Aldrich, Milan, Italy). AP21967 was solubilized in DMA to a concentration of 10 mg/ml. Before use, 3 ml of AP21967/DMA was mixed with 22 ml DMA and 25 ml PEG/Tween; a volume of 50 ml was injected i.p. to deliver a dose of 1.5 mg/kg. Control mice were injected with a preparation of 50% DMA and 50% PEG/Tween; a volume of 50 ml/mouse was administered. Animals were observed closely, and survival studies were then performed. For depletion of endogenous NK function, in a set of experiments, SCID mice were treated i.p. with 30 ml rabbit anti-asialo GM1 antiserum (Wako, Neuss, Germany) on days À1, 7 and 14 and every 7 days thereafter for the duration of the experiment, as detailed elsewhere. 33 
Confocal laser scanning microscopy
Frozen tumor masses embedded in OCT were sliced (5-6 mm thick) and deposited onto poly-L-lysine-coated glass slides before undergoing either staining with hematoxylin and eosin (H&E) or fixation with paraformaldehyde 1% in PBS for 15 min. Slides were washed three times with PBS and then incubated for 1 h at room temperature with a saturating solution consisting of 5% goat serum, 1% BSA and 0.1% Triton-X in PBS. After saturation, the slides were incubated with 1:5000 dilution of propidium iodide (0.1 mg/ml; Transduction Laboratories, Lexington, KY, USA) and 1:200 dilution of rabbit anti-GFP (Molecular Probes, Eugene, OR, USA) in PBSTriton X-100 0.1% for 1 h. After three washes with PBSTriton X-100 0.1%, the slides were incubated with a 1:500 Alexa 488-conjugated anti-rabbit secondary antibody (Ab; green signal). Finally, the slides were washed three times with PBS and mounted before being analyzed by laser scanning microscopy.
In a set of experiments, tumor sections were stained with the following reagents: a rat anti-CD31 Ab (BectonDickinson, Franklin Lakes, NJ, USA) followed by an antirat Alexa594 Ab (Invitrogen); a rabbit anti-cleaved caspase 3 mAb (Cell Signaling, Beverly, MA, USA) followed by an anti-rabbit Alexa 488 Ab (Invitrogen); and the nuclear dye TO-PRO-3 (Invitrogen). Confocal laser scanning microscopy was carried out with a Zeiss LSM 510 microscope using Argon (488 nm) and heliumneon (543 nm) laser sources. Images of tumors were taken at an optical section o5.8 mm using a Â 20 objective (NA 1.3) with the zoom set at 0.7 (512 Â 512 pixels). Laser intensity, pinhole aperture and photomultiplier parameters were standardized and applied to all scannings, enabling direct comparison of signals obtained in different samples.
Cytofluorimetric analysis
Enhanced green fluorescent protein-expressing fibroblasts in tumors were analyzed with an EPICS XL flow cytometer (Coulter Electronics, Hialeah, FL, USA).
Following killing of the mice, tumors were minced with scissors and passed through strainers until a cell suspension was obtained. Cells were then pelleted, washed and fixed with PBS-1% formaldehyde. Parental cell lines served as a negative control for EGFP expression analysis. The mean fluorescence intensity was calculated as reported elsewhere. 34 The membrane expression of the Ly-6C antigen on mouse cells was determined by labeling with a rat anti-murine Ly-6C mAb (Pharmingen, Franklin Lakes, NY, USA), as described elsewhere. 35 The presence of NK cells was determined by staining cells from the peritoneal lavage fluids or splenocytes with a phycoerythrin (PE)-labeled rat anti-mouse pan-NK cells mAb (clone DX5, eBioscience, San Diego, CA, USA).
Molecular analysis
To evaluate the expression of the IFN-responsive IRF7 gene, total RNA was isolated from PBMC using the QIAamp RNA Blood Mini Kit (Qiagen, Milan, Italy) according to the manufacturer's instructions. RNA (1 mg) was treated with DNase to remove any residual genomic DNA from the RNA sample, and used for the synthesis of first-strand cDNA using oligo-dT primers and MLV reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Amplification was performed using the following primers: 5 0 -ATG GCT GAA GTG AGG GGG-3 0 (IRF7-for), 5 0 -GCA GAA CCT GAA GCA AGA GG-3 0 (IRF7-rev). PCR was performed for 26 cycles at 941C for 45 s (melting), 581C for 45 s (annealing) and 721C for 1 min (extension). As an amplification control, the b-actin gene was amplified using the following primer sequences: 5 0 -ACC ATT GGC AAT GAG CGG TT-3 0 (actfor) and 5 0 -TCC TGC TTG CTG ATC CAC AT-3 0 (act-rev). In all experiments, PCR products were analyzed on a 1% agarose electrophoresis gel, and visualized under UV lamps following ethidium bromide staining.
Quantitation of murine interferon-a and human vascular endothelial growth factor and interleukin-8 levels An ELISA assay (PBL Biomedical Laboratories, Piscataway, NY, USA) was used to quantify the levels of murine IFN-a in the supernatants of cells transduced by the retroviral vectors and the peritoneal washings of the treated animals. The range of sensitivity of the assay was 12.5-500 pg/ml; 10 pg IFN-a is considered equivalent to 1 IU of the cytokine. Peritoneal washing fluids were concentrated by 30 to 40-fold by low-speed centrifugation on concentration columns (Millipore, Milan, Italy) according to the manufacturer's instructions. VEGF and IL-8 levels were measured by ELISA kits (Biosource, Camarillo, CA, USA) in 72-h-conditioned medium from IGROV-1 cells plated in P12 wells at 2 Â 10 4 cells/well in the presence of 1-100 ng/ml of either AP21967 or rapamycin (Sigma-Aldrich).
In vitro measurements of interferon-a production
Induction of IFN-a production by NIH3T3 cells transduced with the two components of the inducible retroviral vector system was performed as follows. Briefly, NIH3T3-IFN ind , NIH3T3-IFN const or control NIH3T3 cells were plated in P12 wells at 2 Â 10 4 cells/well. The following day, the medium was replaced with fresh Constitutive versus inducible IFN-a gene therapy of ovarian cancer S Indraccolo et al medium containing 100 ng/ml AP21967. The supernatant was collected at regular intervals thereafter, centrifuged for 15 min at 3000 r.p.m. and stored at À801C until measurement of IFN-a content by ELISA. In a set of experiments, different concentrations of AP21967 (ranging from 1 to 1000 ng/ml) were added to the cells, and the supernatant was collected 24 h later.
Cell proliferation assay
To evaluate the effects of AP21967 or rapamycin on cell proliferation, IGROV-1 or NIH3T3 cells were plated in 96-well plates at 2000 cells/well in complete RPMI or DMEM medium, respectively. One day later, AP21967 or rapamycin was added to the wells (100 ml/well) at different concentrations (range 1-1000 ng/ml). Three days later, cell proliferation was evaluated by an MTT assay, as reported previously. 36 
Histology and immunohistochemistry
Four-mm-thick tumor sections were rehydrated, and either stained with H&E or processed for immunohistochemistry by standard procedures. Tumor vessels were labeled with a rat anti-CD31 Ab (Pharmingen); immunostaining was performed using the avidinbiotin-peroxidase complex technique and 3-3 0 -diaminobenzidine as chromogen (Vector Laboratories, Burlingame, CA, USA), and the sections were then lightly counterstained with Mayer's hematoxylin. Parallel negative controls obtained by replacing primary Abs with PBS were run in all cases. Microvessel areas were quantified by blind counting of hotspots in sections; five representative fields at high magnification ( Â 400) for each tumor were counted.
Statistical analysis
Data were managed using the Statgraphics software. Statistical significance was set at Po0.05. Kaplan-Meier survival curves were analyzed with the median test. The non-parametric Wilcoxon's paired test was used to compare the MVD between IFN-treated and control tumor samples.
